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Objectives: To study the clinical outcome, treatment
response, T-cell subsets and functional consequences of a
novel tumour necrosis factor (TNF) receptor type 1
(TNFRSF1A) mutation affecting the receptor
cleavage site.
Methods: Patients with symptoms suggestive of tumour
necrosis factor receptor-associated periodic syndrome
(TRAPS) and 22 healthy controls (HC) were screened for
mutations in the TNFRSF1A gene. Soluble TNFRSF1A and
inflammatory cytokines were measured by ELISAs.
TNFRSF1A shedding was examined by stimulation of
peripheral blood mononuclear cells (PBMCs) with phorbol
12-myristate 13-acetate followed by flow cytometric
analysis (FACS). Apoptosis of PBMCs was studied by
stimulation with TNFa in the presence of cycloheximide
and annexin V staining. T cell phenotypes were monitored
by FACS.
Results: TNFRSF1A sequencing disclosed a novel V173D/
p.Val202Asp substitution encoded by exon 6 in one
family, the c.194–14G.A splice variant in another and
the R92Q/p.Arg121Gln substitution in two families.
Cardiovascular complications (lethal heart attack and
peripheral arterial thrombosis) developed in two V173D
patients. Subsequent etanercept treatment of the V173D
carriers was highly effective over an 18-month follow-up
period. Serum TNFRSF1A levels did not differ between
TRAPS patients and HC, while TNFRSF1A cleavage from
monocytes was significantly reduced in V173D and R92Q
patients. TNFa-induced apoptosis of PBMCs and T-cell
senescence were comparable between V173D patients
and HC.
Conclusions: The TNFRSF1A V173D cleavage site
mutation may be associated with an increased risk for
cardiovascular complications and shows a strong
response to etanercept. T-cell senescence does not seem
to have a pathogenetic role in affected patients.
Hereditary autoinflammatory syndromes are char-
acterised by recurrent multisystemic inflammation
with increased acute phase reactants, but absent
infection, high-titre autoantibodies or antigen-
specific T lymphocytes (reviewed by Stojanov
and Kastner1). The tumour necrosis factor recep-
tor-associated periodic syndrome (TRAPS;
Mendelian inheritance in man no 142680) is the
most common autosomal dominantly inherited
autoinflammatory syndrome affecting patients of
diverse ethnicities.2 Characteristic clinical features
are recurrent and prolonged (.5 days) episodes of
fever in conjunction with severe abdominal pain,
centrifugally migrating localised myalgia with
associated painful erythematous skin rash as well
as conjunctivitis and unilateral periorbital
oedema.3 4
TRAPS is caused by sequence alterations in the
TNFRSF1A gene on chromosome 12p13, which
encodes the ubiquitously expressed 55 kDa TNF
receptor (TNFRSF1A, CD120a).2 More than 50
TRAPS-related mutations have been reported so far
(INFEVERS database at http://fmf.igh.cnrs.fr/inf-
evers (accessed 29 May 2008)5). The majority are
single nucleotide missense mutations within
TNFRSF1A exons 2, 3 and 4, affecting the first
three of four extracellular cysteine-rich domains of
the receptor. R92Q, a TNFRSF1A variant encoded
by exon 4, is found in 1–2.5% of the normal
population and presents with an incomplete
penetrance and milder or TRAPS-atypical clinical
features.6–9 To date, only two mutations have been
reported in exon 6: (a) I170N/p.Ile199Asn,10 an
amino acid substitution very close to the
TNFRSF1A cleavage site (between p.Asn201 and
p.Val202), which is adjacent to the transmembrane
domain of TNFRSF1A11 12 and (b) L167_G175del/
p.Leu196_Gly204del,9 the first large in-frame inter-
stitial deletion.
The TRAPS episodes were initially considered to
be the consequence of a diminished antagonistic
effect of soluble TNF receptors owing to an
impaired activation-induced receptor cleavage
(shedding), leading to an increase of unbound
TNFa in the circulation.2 However, affected
members of the first thoroughly described TRAPS
family showed raised levels of interleukin 6 (IL6)
and IL8, but not of TNFa,13 14 suggesting additional
pathogenetic mechanisms. Recent experiments
have shown a more complex situation with
mutation- and cell type-dependent TNF receptor
cleavage defects,15 TNF-independent NF-kB activa-
tion16 and impairment of intracellular TNF recep-
tor trafficking, TNF binding17 and TNF-induced
apoptosis,9 18 probably caused by misfolding of the
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extracellular domain of TNFRSF1A and leading to retention of
the mutated receptors in the endoplasmic reticulum.19
The prognosis of TRAPS is mainly dependent on the
development of systemic AA amyloidosis, which occurs in up
to 14% of mutation-positive patients and asymptomatic
carriers,3 therefore warranting an efficient treatment.
Although corticosteroids can be quite effective in more severe
episodes, patients often require escalating doses, with subse-
quent side effects. Lately, etanercept, a TNFa-neutralising
agent, has been shown to elicit a beneficial therapeutic response
in many patients (reviewed by Stojanov and McDermott4).
Here, we report a new TNFRSF1A mutation at the receptor
cleavage site in an Austrian family. Two of the four affected
members presented with cardiovascular complications. The
V173D mutation was characterised by receptor shedding in
comparison with two other TNRSF1A mutations and the
treatment effect of etanercept was studied. The question of
T-cell senescence in TRAPS patients was also examined.
PATIENTS AND METHODS
Study participants
We included the members of four families carrying one of three
different TRAPS-causing TNFRSF1A mutations, one of which
was a novel mutation affecting the receptor cleavage site. One
family was of Austrian, two of German and one of German/
Spanish ancestry. The probands or their parents, or both,
were asked about their clinical symptoms and disease history.
A family history was present in one affected family. Blood was
taken from all family members and also from 22 healthy
Caucasian subjects, who served as normal controls. The study
was approved by the ethics committee of the Innsbruck Medical
University, Austria. Written informed consent was obtained
from all participants or their parents before enrolment.
DNA extraction and sequence analysis of the TNFRSF1A, MVK,
MEFV and NLRP3/CIAS1 genes
EDTA blood samples were collected from all participants and
genomic DNA was extracted from white blood cells using the
QIAamp blood mini-kit (Qiagen, Hilden, Germany). After
amplification by PCR, TNFRSF1A exons 2, 3, 4 and 6 were
sequenced. MVK exons 9 and 11, MEFV exons 2 and 10 and
NLRP3/CIAS1 exon 3 were also analysed in order to exclude
common mutations resulting in other hereditary autoinflam-
matory fever syndromes.20 21
Determination of soluble TNF receptors in serum and culture
supernatants
Soluble tumour necrosis factor receptor superfamily 1A
(sTNFRSF1A) and 1B (sTNFRSF1B) were measured in serum
samples obtained from TNFRSF1A mutation-positive family
members between attacks and from healthy controls (HC) as
well as in culture supernatants of stimulated peripheral blood
mononuclear cells (PBMCs) using ELISA kits (Bender
MedSystems, Vienna, Austria) according to the manufacturer’s
Figure 1 New TNFRSF1A cleavage site mutation V173D and pedigrees of the TRAPS families investigated. (A) Partial TNFRSF1A exon 6 sequence of
a normal subject (left panel) and of a heterozygous mutation carrier (right panel). The arrow indicates the position of the TRA nucleotide substitution,
resulting in a valine (GTT)-to-aspartic acid (GAT) exchange at amino acid position 173 of the mature protein. (B) Pedigrees of the four families with
tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS) caused by three different TNFRSF1A mutations, c.605T.A/V173D,
c.194–14G.A and c.362G.A/R92Q. Open symbols represent healthy subjects, solid symbols affected subjects and grey symbols healthy carriers.
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instructions. The detection limits of the assays were ,53 pg/ml
for sTNFRSF1A and ,99 pg/ml for sTNFRSF1B. Samples from
patients (but not from controls) were analysed in duplicate and
the mean of the two values was calculated. Investigators were
blinded to the identity of all samples.
Cell activation and flow cytometric analysis
To study cleavage of the extracellular domain of TNFRSF1A,
PBMCs were isolated from patients with TRAPS and from HC
as previously described.22 Assays using PBMCs from healthy and
affected family members were performed in parallel and
investigators were unaware of the results of the TNFRSF1A
mutation analysis. Data from healthy family members were
allocated to the HC group.
PBMCs were stimulated with phorbol 12-myristate 13-
acetate (PMA; Sigma, Munich, Germany) for 25 min at 37uC.
The optimal concentration of PMA was critical for performance
of the shedding assays. In a preliminary study, concentrations
ranging from 1 to 20 ng/ml induced optimal shedding in HC
without destroying cells. After washing, cells were stained for
30 min at 4uC with fluorescein isothiocyanate (FITC)-conju-
gated anti-CD120a (TNFRSF1A) monoclonal antibody (mAb)
and peridinin chlorophyll protein-conjugated anti-CD14 (mono-
cytes) and anti-CD3 (T cells) (Becton Dickinson, San Diego,
California, USA).23 Corresponding isotype control antibodies
were used.
For T-cell subtype analysis, freshly isolated PBMCs were
stained with FITC-conjugated mAbs (CD4, CD25, CD28 and
CD45RA), phycoerythrin-conjugated mAbs (CD28 and
CD45RO) and peridinin chlorophyll protein-conjugated mAbs
(CD3, CD4 or CD8), as appropriate.
Stained cells were analysed on a FACS-Calibur (Becton
Dickinson). At least 10 000 events were counted for each
acquisition. Data were analysed using the WinMDI software
(version 2.5, Joseph Trotter, Scripps Research Institute, La Jolla,
California, USA).
Study of TNF-induced apoptosis in PBMCs
Apoptosis assays were performed as previously described.18
Briefly, freshly isolated PBMCs (16106) were stimulated with
0, 1, 10 and 100 ng/ml TNFa and cycloheximide (50 mg/ml,
Sigma) either alone or in combination for 6 h at 37uC. Apoptosis
was analysed using FITC-conjugated annexin V staining
(Becton Dickinson) and flow cytometry.
Statistical analysis
Statistical analyses were performed using the SPSS program,
version 12.0. The Kolmogorov–Smirnov test was used to test
for normal distribution. Parametric and non-parametric
tests, including the Student t test, Mann–Whitney U,
Wilcoxon, Kruskal–Wallis and Friedman tests, were used as
appropriate. To test for shedding differences between patients
and controls, ratios and differences between stimulated and
unstimulated cells were calculated to adjust for differences in a
priori receptor expression. p Values ,0.05 were considered
significant.
Table 1 Clinical and laboratory characteristics of TNFRSF1A mutation-positive family members
Characteristics
Family member
1-I.2 1-II.1 1-II.2 1-II.3 2-I.2 2-II.3 3-I.1 3-II.1 3-II.2 4-I.1 4-II.2 4-II.3
Ethnicity Austrian Austrian Austrian Austrian German German German German/Spanish German/Spanish German German German
Gender F M F M F F M F M M F M
Age (years) 46 26 Deceased 23 57 15 44 8 5 53 21 12
Age at disease
onset (years)
6 1 6 5 – 12 – 3 – – – 10
Duration of fever (days) 4–5 3–7 7 3 – 1–7 – 1–5 – – – 28–56
Fever-free interval (weeks) 4 4 3 4 – 4–24 – 2–12 – – – 24
Abdominal pain – + – + – – – ++ – – – –
Vomiting + – + + – – – + – – – –
Hepatomegaly – – – + – – – – – – – –
Myalgia ++ – + – – – – – – – – +
Rash + ++ + + – – – – – – – +
Conjunctivitis – – – – – – – – – – – +
Arthralgia ++ + + ++ – – – + – – – ++
Arthritis + – + – – – – – – – – –
Headache – – – – – + – – – – – +
Pharyngitis – + + – – ++ – ++ – – – –
Lymphadenopathy – + – – – + – – – – – –
Amyloidosis – – – – – – – Mild proteinuria – – – –
Mutation in the TNFRSF1A
gene




R92Q R92Q R92Q R92Q R92Q R92Q
Leucocytes 6109/l 8.8{ Normal*{ 11.2* 3.8*, 8.6{ Normal 5.1{ NA 11.5*, 7.1{ 8.2 NA NA 5.8{
CRP (mg/l) 27{ 590*, 121{ 381{ 269*, normal{ Normal 0.5{ NA 38*, ,0.5{ ,0.5 NA NA ,0.5{
SAA (mg/l) ND 773* ND ND NA 110*, ,0.7{ NA 220*, 2.3{ 1.4 NA NA 5.2{
ESR (mm/1st h) 60{ 90*, 72{ ND 105*, 16{ NA 7{ NA 19* 6 NA NA 6{
Fibrinogen (g/l) 5.50{ 8.85{ 10.0*,
4.32{
10.59* NA ND NA ND ND NA NA ND
*Highest documented value measured during an attack; {highest documented value measured between attacks.
CRP, C-reactive protein (normal ,5 mg/l); ESR, erythrocyte sedimentation rate (normal ,10 mm/1st h); NA, not available; ND, not determined; SAA, serum amyloid A (normal
,5 mg/l); ++, severe; +, present; 2, absent.
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RESULTS
TNFRSF1A mutation detection
Sequence analysis of exons 2, 3, 4 and 6 of the TNFRSF1A gene
in the index patient of family 1 revealed a novel heterozygous
GTT to GAT transversion in exon 6, resulting in a valine-to-
asparagine substitution at residue 173 (V173D/p.Val202Asp)
(fig 1A). This amino acid exchange directly affects the major
receptor cleavage site, which is located between p.Asn201 and
p.Val202. This mutation was present in all family members
except the healthy father and one healthy sister (fig 1B) and was
not detected in more than 2000 control chromosomes. Three
additional TNFRSF1A mutation-positive families were included,
of which family 2 demonstrated heterozygosity for c.194–
14G.A, a known TNFRSF1A splice site mutation, while
families 3 and 4 were positive for the low-penetrance
TNFRSF1A mutation R92Q (fig 1B).
The V173D mutation is associated with TRAPS: typical clinical
features, atypical complications and sustained clinical response
to etanercept
Table 1 summarises the main clinical signs/symptoms and
laboratory findings of the 11 TNFRSF1A mutation-positive
subjects.
The male:female ratio was 6:5. Most of the TRAPS
characteristic features were associated with the fully penetrant
V173D substitution in family 1. Cardiovascular complications
developed in two affected family 1 members. After a severe
gastroenteritis, the V173D-heterozygous sister (1-II.2) of the
index patient (1-II.1) died at the age of 22 years owing to heart
failure associated with myocardial infarction with subsequent
ventricular thrombosis and A cerebri media infarction.
Serological antibody screening for viruses was negative. At the
age of 21 years, her brother (1-II.3) developed an arterial
thrombosis of the left A poplitea owing to cystic degeneration
of the intima, warranting local desobliteration with thrombect-
omy and subsequent oral anticoagulation. None of the affected
patients were active smokers. A thorough analysis of the
coagulation system (including screening for known hereditary
coagulopathies) in all members of family 1 did not show any
anomalies at five consecutive clinical visits, except for highly
increased fibrinogen concentrations in all TNFRSF1A mutation-
positive family members. Repeated assessments of antipho-
spholipid antibodies, including anticardiolipin and b2-micro-
globulin antibodies as well as lupus anticoagulant, also yielded
negative results.
All affected family 1 members were initially treated with
various non-steroidal anti-inflammatory drugs and cumulative
doses of glucocorticosteroids. However, reduction of the
intensity of disease-associated symptoms was limited. In
contrast, all clinically affected patients of families 2–4
responded to steroid treatment with shortening of the fever
episodes or rapid cessation of symptoms, or both.
After diagnosis of TRAPS, TNFa-blocking treatment with
25 mg etanercept (Enbrel; Wyeth, Philadelphia, USA) twice
weekly was started in all affected family 1 members. All three
patients (patient 1-II.2 had already died) showed an immediate
response and remained symptom-free with etanercept treat-
ment until the end of follow-up after 18 months. Table 2 shows
the measurements of acute phase reactants and proinflamma-
tory cytokines before and after etanercept treatment.
Normal serum levels of sTNFRSF1A and sTNFRSF1B in patients
with TRAPS
Median serum concentrations of sTNFRSF1A and sTNFRSF1B
were 1.8 ng/ml (range 0.92–3.0) and 5.52 ng/ml (0.92–36.6) in
HC. sTNFRSF1A and sTNFRSF1B levels of patients affected by
the V173D (sTNFRSF1A median 1.8 ng/ml, range 1.2–2.6 and
sTNFRSF1B median 8.0 ng/ml, range 4.8–13.1), the c.194–
14G.A and the R92Q mutation did not differ from HC (fig 2A).
Impaired shedding of TNFRSF1A from stimulated monocytes in
patients with the V173D and R92Q mutations
Stimulation with PMA induced shedding of TNFRSF1A from
CD14+ monocytes in all TRAPS patients and HC (figs 2B and
C). Compared with HC, however, TNFRSF1A shedding was
reduced in patients with the V173D (mean (SEM) 86.2 (2.6)% vs
95.1 (2.4)%; p,0.05 at a dosage of 10 ng/ml PMA) and the
R92Q substitution, but not in patients with the c.194–14G.A
mutation. Levels of sTNFRSF1A in supernatants of PBMCs
showed a comparable increase in patients and HC after
stimulation with PMA (fig 2D).
Normal induction of apoptosis in TNFa-stimulated PBMCs from
patients with the V173D mutation
To assess whether the V173D mutation is associated with
functional alterations other than TNF receptor cleavage, TNFa-
induced apoptosis was analysed in PBMCs from patients
carrying the V173D mutation and from HC. After stimulation
of PBMCs with 0, 1, 10 and 100 ng/ml TNFa in the presence of
cycloheximide for 6 h, a similar percentage of cells were annexin
V positive in V173D heterozygotes (mean (SEM) ratio 1 ng/ml
vs unstimulated 17.2 (12.0); vs 10 ng/ml 16.2 (12.0) and vs
100 ng/ml 20.3 (8.7)) and in HC (11.5 (4.9), 23.2 (5.9) and 22.2
(4.5)), respectively) (fig 3).
Table 2 Effect of etanercept treatment on serum acute phase
parameters as well as tumour necrosis factor a and interleukin 6
concentrations in V173D mutation-positive family members
1-I.2 1-II.1 1-II.3
CRP (mg/l)
Before etanercept 26 121 268
Etanercept for 3 months 10 1 7
Etanercept for 6 months 108 3.1 1
Etanercept for 12 months 4 18.5 39
ESR (mm/1st h)
Before etanercept 60 72 70
Etanercept for 3 months 16 4 8
Etanercept for 6 months 1 6 10
Etanercept for 12 months 8 8 14
TNFa (pg/ml)
Before etanercept 19 15 64
Etanercept for 3 months 251 190 198
Etanercept for 6 months 111 86 96
Etanercept for 12 months 37 30 36
IL6 (pg/ml)
Before etanercept 3 3 82
Etanercept for 3 months 3 10 3
Etanercept for 6 months 7 ,3 3
Etanercept for 12 months 4 ,3 5
CRP, C-reactive protein (normal ,5 mg/l); ESR, erythrocyte sedimentation rate
(normal ,10 mm/1st h); IL6, interleukin 6 (normal ,3 pg/ml); TNFa, tumour necrosis
factor a (normal ,20 pg/ml).
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Absence of T-cell senescence in patients with the V173D
mutation
Because chronic TNFa receptor signalling is known to induce T-
cell senescence,24 we investigated whether T-cell subsets are
altered in patients with the V173D mutation. Table 3 shows
that the prevalences of CD4+CD25+ activated T cells,
CD4+CD45RA+ and CD8+CD45RA+ naı¨ve T cells,
CD4+CD45RO+ and CD8+CD45RO+ memory T cells as well
as CD4+CD282 and CD8+CD28- memory/effector T cells did
not differ from HC and did not change significantly after TNFa-
blocking therapy.
DISCUSSION
The novel TNFRSF1A mutation V173D/p.Val202Asp encoded
by exon 6 of the TNFRSF1A gene is unique, since it directly
affects the receptor cleavage site, which is located between
p.Asn201 and p.Val202.11 12 All V173D carriers presented with a
fully penetrant TRAPS phenotype. Two of them developed
cardiovascular complications in addition, leading to the death of
one sister due to myocardial infarction and to the development
of arterial thrombosis in one brother. None of the mutation-
positive family members showed any coagulation abnormality
and hyperfibrinogenaemia as the sole cause of these complica-
tions seems to be unlikely.
Figure 2 TNFRSF1A shedding in patients with different TNFRSF1A mutations and in healthy controls. (A) Normal levels of soluble TNF receptor
superfamily 1A (sTNFRSF1A) and 1B (sTNFRSF1B) in patients with the V173D mutation. Levels of sTNFRSF1A and sTNFRSF1B in serum samples from
patients with the TNFRSF1A mutations c.605T.A/V173D (n = 3), c.194–14G.A (n = 2) and c.362G.A/R92Q (n = 4) and from healthy controls
(n = 21) were determined by ELISA. Each dot represents the mean of two identical aliquots from a patient, while horizontal lines indicate the median
values. (B, C) Impaired shedding of TNFRSF1A from stimulated CD14+ monocytes in patients with the V173D and R92Q mutations. (B) Representative
histograms show expression of TNFRSF1A (filled curve; the black line represents isotype control) on CD14+ cells from a patient with the V173D
mutation and a healthy control without and after stimulation with 1, 10 and 20 ng/ml phorbol 12-myristate 13-acetate (PMA) for 25 min at 37uC. MFI,
mean fluorescence intensity. (C) Error bars summarise TNFRSF1A shedding from CD14+ cells of healthy controls (n = 26) and from patients with the
V173D (n = 3), the R92Q (n = 4) and the c.194–14G.A (n = 2) mutation after stimulation with 10 ng/ml PMA. Data are shown as the mean (95%
confidence interval) percentage change (ratio (MFI stimulated/MFI unstimulated cells)6100). (D) Comparable increment of levels of sTNFRSF1A in the
supernatant of peripheral blood mononuclear cells from TRAPS patients and healthy controls after stimulation with 10 ng/ml PMA. Error bars indicate
the mean (95% confidence interval) difference of sTNFRSF1A before and after stimulation. *p,0.05 according to the Student t test; NS, not significant.
Figure 3 Tumour necrosis factor a (TNFa)-induced apoptosis is not
altered in V173D heterozygotes. Freshly isolated peripheral blood
mononuclear cells from patients carrying the V173D mutation (n = 3)
and from healthy controls (n = 6) were incubated for 6 h at 37uC with
different doses of TNFa in combination with 50 mg/ml cycloheximide as
indicated. Boxes indicate the mean (SEM) increase of annexin V-positive
cells as a percentage compared with cells incubated with cycloheximide
only. Differences were not significant (NS) according to the
Student t test.
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An increased risk of atherosclerosis has been suggested for
R92Q carriers in a large European study of subjects with
myocardial infarction.25 Furthermore, six R92Q carriers with
Behc¸et disease developed extracranial venous thrombosis.26
Pericarditis and myocarditis have also been reported in R92Q7
and P46L—another low-penetrance variant—heterozygotes.27
To assess a potential association of our novel V173D mutation
with atherosclerosis, young patients presenting with cardiovas-
cular disease should be screened for this TNFRSF1A receptor
cleavage site mutation.
The V173D/p.Val202Asp mutation may have an atherogenic
effect, as TNFa is involved in the development of endothelial
dysfunction and atherosclerosis, probably potentiated by the
prolonged increase of acute phase parameters.28 Another
possibility is the development of amyloidosis with subsequent
cardiomyopathy. However, except for the deceased patient,
who was not examined for amyloidosis post mortem, none of
the mutation-positive family members showed any clinical
signs of amyloidosis. It has also been suggested that TNFRSF1A
mutations interfere with the local antithrombotic effect of
TNFa during inflammation by impairing the endothelial TNF
receptor-mediated iNOS stimulation.26 A link between prema-
ture T-cell ageing, early atherosclerotic damage and multivessel
coronary artery disease as established for rheumatoid arthritis
and unstable angina,29–31 on the other hand, seems unlikely for
patients carrying TNFRSF1A mutations because concentrations
of CD282 T cells as a marker of early T-cell ageing were normal
in our V173D patients.
Earlier in vitro experiments had demonstrated that
TNFRSF1A shedding is partially impaired when the valine
residue at position 202 is substituted by aspartic acid, glycine
or arginine, whereas replacement with proline resulted in a
marked decrease in shedding.12 Accordingly, monocytes from our
TRAPS patients with the V173D/p.Val202Asp mutation
showed a partially, but significantly reduced shedding compared
with HC. Levels of sTNFRSF1A, in contrast, increased to a
comparable extent in PBMC supernatants after stimulation.
One reason for this discrepancy may be that the sTNFRSF1A
concentrations measured by ELISA were near the detection
limit of the assay, causing some imprecision. Alternatively, and
as already described for other TRAPS mutations, receptor
shedding may differ between various cell types.15 This hypoth-
esis is corroborated by our results for the R92Q and c.194–
14G.A mutations, which are consistent with previously
published data.6 9 Furthermore, our results suggest that the
normal receptor protein synthesised from the intact allele
compensates in part for the cleavage deficiency, at least in
monocytes.
TNFa-induced apoptosis of PBMCs in our V173D patients did
not differ from that of HC. However, as we did not analyse
other cell types such as fibroblasts or neutrophils, for which
apoptotic resistance has been described in TRAPS patients
carrying cysteine mutations,9 18 we cannot completely rule out
such a defect in our V173D patients. Whether TNFRSF1A
cleavage site mutations, including the V173D variant, cause
functional impairments in addition to the TNFRSF1A shedding
defect awaits further investigations.
Owing to the limited responsiveness of our V173D patients to
non-steroidal anti-inflammatory drugs and steroids and the
suggested receptor shedding defect, we started anti-TNFa
therapy with etanercept. All patients responded with cessation
of their clinical symptoms shortly after the start of treatment.
The associated sharp rise in TNFa serum levels seen in our
patients is consistent with previous findings about the ‘‘buffer’’
function of sTNFRSF1A which can continually release TNFa
into the circulation.14 Under sustained etanercept treatment,
however, the TNFa levels declined and remained only slightly
raised in all patients. The effectiveness of etanercept treatment
in our patients with an obvious TRAPS phenotype again
confirms the results of the in vitro experiments performed
earlier by Brakebusch et al.12
In summary, we have identified a new TNFRSF1A muta-
tion directly affecting the receptor cleavage site, which is
associated with a severe TRAPS phenotype and cardiovascular
complications. Despite an associated partial shedding defect,
patients had normal serum levels of sTNFRSF1A and TNFa, but
were highly responsive to etanercept treatment over the course
of 1K years.
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Naı¨ve (CD28+CD45RA+) 67.0 (59.3–71.7) 29.0 (23.0–32.7) 44.7 (27.8–69.3)
Memory (CD28+CD45RO+) 41.3 (24.1–43.5) 46.8 (35.3–52.4) 45.2 (30.5–68.1)
Memory-effector (CD28–) 0.2 (0.1–0.3) 0.7 (0.2–0.9) 0.7 (0–38.0)
Activated (CD25+) 25.0 (6.8–32.4) 7.8 (6.6–9.6) 12.3 (3.0–26.4)
CD8+ T cells
Naı¨ve (CD28+CD45RA+) 77.8 (63.9–90.2) 70.5 (42.4–71.8) 45.9 (14.5–65.2)
Memory (CD28+CD45RO+) 11.0 (1.6–40.8) 12.4 (6.1–39.4) 19.8 (6.3–51.8)
Memory-effector (CD28–) 19.2 (5.9–25.7) 14.2 (1.9–28.2) 21.9 (7.6–77.4)
Activated (CD25+) ND 0.9 (0.8–1.0) 2.7 (0.4–10.5)
Data are shown as the median (range) percentage of CD4+ and CD8+ T cells, respectively. ND, not done.
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